ClinicalTrials.gg
RecruitingNCT07609862Updated Jul 30, 2026

A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies

A Phase 1/2 interventional study of Lacutoclax+Rocbrutinib in Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma ( FL), sponsored by Guangzhou Lupeng Pharmaceutical Company LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Guangzhou Lupeng Pharmaceutical Company LTD. (part of Lupeng Pharmaceutical Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.

Planned enrollment
31st of 91
92 · median 50
Started
2026
with 9 others
Phase 1/2
24 of 98
7 open now
Primary completion
2029-06
later than 42 of 55 live
Registered
93rd of 98
by date
Lead sponsor
4 of 98
Guangzhou Lupeng Pharmaceutical Company LTD.

Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 31st largest by planned enrollment of the 91 interventional ones that give a count, is one of 10 that started in 2026, is one of 24 in phase 1/2, reaches primary completion later than 42 of the 55 other live ones, and was the 93rd registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lymphoma, Mantle-Cell with a site in China, or all of them as a file.
02

Study summary

BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit. This is a multi-center, open-label, single-arm Phase Ib/II clinical study. The purpose of this clinical trial is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of Rocbrutinib, a fourth-generation Bruton tyrosine kinase inhibitor (BTKi), in combination with the BCL-2 inhibitor Lacutoclax in patients with mature B-cell malignancies. The Phase Ib will use a classic 3+3 dose-escalation design to evaluate dose-limiting toxicities (DLTs), determine the maximum tolerated dose (MTD), and identify the recommended dosing regimen. The Phase II portion is intended to further evaluate the efficacy and safety of the combination therapy.

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Follicular Lymphoma ( FL)
  • Waldenström Macroglobulinemia (WM)
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Keywords

  • mature B-cell malignancies
  • BTK inhibitor
  • BCL-2 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, regardless of sex.
  2. Ib: confirmed diagnosis of CLL/SLL (per 2018 iwCLL criteria) or B-cell (per 2022 WHO classification), including: MCL, DLBCL, FL, and WM. Must have received at least one , with documented disease progression or intolerance.

    II: For Treatment-naïve (TN) CLL/SLL patients: Must meet iwCLL treatment indications and no prior systemic therapy. For R/R CLL/SLL patients: at least one prior systemic therapy with documented disease progression or intolerance.

  3. Have at least one .
  4. Phase Ib: performance status ≤1; phase II: ECOG performance status ≤2.
  5. ≥ 12 weeks.
  6. Adequate coagulation function, liver and kidney function, bone marrow hematopoietic function.
  7. Male patients and female patients of must agree to use effective during the study and for 90 days after the last dose of study treatment. Female patients of childbearing potential must have a negative pregnancy test before study treatment and must not be breastfeeding. Male patients must not donate sperm during the study and for 90 days after the last dose.
  8. Participation is voluntary, requiring signed and compliance with the treatment regimen and visit schedule.

Exclusion criteria

Exclusion Criteria:

  1. Known or intolerance to Rocbrutinib, Lacutoclax, or any of their ; prior treatment with any BCL-2 inhibitor; or prior treatment with both covalent and non-covalent BTK inhibitors.
  2. Use of systemic at doses equivalent to >20 mg/day of prednisone for ≥3 days within 7 days prior to the first dose.
  3. History of or currently suspected Richter's syndrome.
  4. Known or suspected central nervous system (CNS) involvement.
  5. Prior hematopoietic stem cell transplantation (allo-HSCT), or autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy within 90 days before the first dose of study treatment.
  6. Received antitumor therapy, agents, major surgery, severe trauma, or within 4 weeks or 5 half-lives prior to the first dose of study treatment.
  7. Received herbal medicines for antitumor treatment, or localized radiotherapy within 14 days prior to the first dose of study treatment.
  8. Use of moderate or strong inhibitors within 7 days prior to the first dose of study treatment, or consumption of grapefruit, grapefruit juice, starfruit, or Seville oranges within 3 days prior to prior to the first dose.
  9. History of other active within the past 3 years, except for curatively treated basal cell carcinoma, localized squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other malignancies considered cured.
  10. Any severe and/or uncontrolled systemic disease, or any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.
  11. Any of the following events within 6 months prior to the first dose: Symptomatic arrhythmia, myocardial infarction, intracranial hemorrhage, or Stroke.
  12. Impaired cardiac function.
  13. Any uncontrolled systemic infection.
  14. Conditions that may impair oral drug administration or significantly affect absorption or pharmacokinetics of the study drug.
  15. Unable to discontinue moderate or strong CYP3A inhibitors or inducers, P-gp (P-glycoprotein) inhibitors, sensitive substrates of OATP1B3 or CYP2C8 during the study period.
  16. Received vaccination with any live-attenuated vaccines within 4 weeks prior to the first dose of study treatment.
  17. Evidence of an active bleeding constitution or a history of significant hemorrhagic disorders.
  18. Requirement for ongoing therapy with warfarin or other vitamin K antagonists.
  19. Presence of an active, uncontrolled, or symptomatic disease that requires systemic treatment.
  20. Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Lacutoclax+Rocbrutinib

    Drug: Lacutoclax+Rocbrutinib

Interventions

  • DrugLacutoclax+Rocbrutinib

    Drug pages: Lacutoclax · Rocbrutinib

    Phase Ib dose-escalation study of Rocbrutinib in combination with Lacutoclax. Rocbrutinib will be administered at a fixed dose of 150 mg once daily (QD), while Lacutoclax will be dose-escalated. Initial dose levels include Lacutoclax 200 mg QD and 400 mg QD in 28-day treatment cycles.Treatment will continue until disease progression, unacceptable toxicity/intolerance, or completion of the protocol-defined treatment duration, whichever occurs first. In phase II, participants will receive Rocbrutinib monotherapy for 8-12 weeks prior to combination treatment. Upon initiation of combination therapy, Lacutoclax will undergo dose ramp-up to the target dose and will then be administered continuously at the target dose. Treatment will continue until disease progression, unacceptable toxicity/intolerance, or completion of the protocol-defined treatment duration, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Phase Ib: Dose-limiting toxicity (DLT)

    Time frame: At the end of Cycle 1 (the length of cycle 1 is 28 days)

  2. Phase Ib: Maximum Tolerated Dose (MTD)

    Time frame: At the end of Cycle 1 (the length of cycle 1 is 28 days)

  3. Phase Ib: Adverse events as assessed by CTCAE v5.0

    Time frame: From the first administration to 28 days after the last administration

  4. Phase Ib: Time to Maximum Plasma Concentration (Tmax)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  5. Phase Ib: Maximum Plasma Concentration (Cmax)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  6. Phase Ib: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t (AUC0-t)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  7. Phase Ib: Half-life (t1/2)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  8. Phase II: Undetectable minimal residual disease (uMRD) rate assessed by flow cytometry

    Time frame: Up to approximately three years

Secondary outcomes

  1. Phase II: Maximum Plasma Concentration (Cmax)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  2. Phase II: Time to Maximum Plasma Concentration (Tmax)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  3. Phase II: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t (AUC0-t)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  4. Phase II: Half-life (t1/2)

    Time frame: From 1 hour prior to administration to 24 hours post-dose

  5. Overall Response Rate(ORR)

    Time frame: Up to approximately three years

  6. Progression-free Survival(PFS)

    Time frame: Up to approximately three years

  7. Overall Survival(OS)

    Time frame: Up to approximately three years

  8. Phase II: Adverse events as assessed by CTCAE v5.0

    Time frame: From the first administration to 28 days after the last administration

  9. Complete Response Rate (CRR)

    Time frame: Up to approximately three years

  10. Duration of Response (DOR)

    Time frame: Up to approximately three years

  11. Phase Ib: Undetectable Minimal Residual Disease (uMRD) Rate assessed by flow cytometry

    Time frame: Up to approximately three years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2029, 35 months after the start.

Of 77 phase 1/2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 114. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartActual
Jul 14, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
May 30, 2033
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07609862
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jul 14, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
May 30, 2033 (estimated)
Last update
Jul 30, 2026

Study contacts

Lugui Qiu
Contact
qiulg@ihcams.ac.cn
+86-13821266636

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lacutoclax · Rocbrutinib

Start the discussion